Karen Boezi has been involved in building, leading and investing in biopharmaceutical companies for more than 30 years. Karen is currently the COO of Thirona Bio, a company focused on developing organ-selective drugs targeting TGF-β for the treatment of fibrotic diseases, including skin and lung fibrosis, as well as cancer. Previously, Karen was the CEO of Redwood Bioscience, leading the company through its successful sale to Catalent (CTLT) under a staged acquisition option, which she closed in less than four years after joining the founding team. Redwood, now a division of Catalent Biologics, continues to be a pioneer in developing antibody-drug conjugates (ADCs) and toxin-linker technology for improving oncology care. Based on research from the lab of Nobel Laureate, Carolyn Bertozzi, PhD, the Redwood division now has multiple collaborators using the platform, including Exelixis, outlicensed proprietary ADCs and is developing other conjugates internally. Prior to joining Redwood, Karen was a founding Partner of Thomas, McNerney & Partners (TMP), a health care technology-focused venture firm with $600 million under management. She launched TMP with a colleague from Warburg, Pincus, where she was a member of the seed stage life science team, and a partner from Coral Ventures, where she was a General Partner. TMP was recognized for managing one of the top performing 2006 vintage venture funds globally. During her venture career, she invested in 15 companies that went public and/or were acquired including Coulter Pharmaceuticals (CLTR, acquired by Corixa) which commercialized one of the first radiolabeled conjugates, Bexxar. She launched three companies with scientific founders including NeXagen (NXGN/NXTR) which led to the commercialization of Macugen after the Gilead Sciences (GILD) acquisition and Eyetech spin-out (EYET, acquired by OSI), at which time Somalogic (SLGC) also was spun-out. Karen began her career as a member of Alex. Brown & Sons’s health care and insurance corporate finance teams. More recently, Karen has been an angel investor and advisor to academic scientists founding biopharmaceutical companies, including Design Therapeutics (DSGN), Bioniz (acquired by EQ) and Acrigen Bioscience, a gene-editing company on whose Board she serves. She graduated Phi Beta Kappa with a B.S. in Economics from the Wharton School at the University of Pennsylvania.